
Event details
Glenn Cohen, Nicholson Price, and Katharina Ó Cathaoiron on Bias in Medical AI
Description
LAW IN LIFE SCIENCE TALK with Professor Glenn Cohen, Harvard Law School Petrie-Flom Center, Professor Nicholson Price, University of Michigan Law School, and Professor Katharina Ó Cathaoir. Moderated by Professor Timo Minssen, CeBIL, University of Copenhagen
With a focus on life science our distinguished speakers will talk on subjects such as "Medical AI: Contextual bias, liability, and regulation", "Label Bias, Informed Consent, Explainability, and Promise and Peril of ChatGPT", and "Medical AI: GDPR and informed consent in Nordic law".
Registration
Please register no later than the 15 June 2023 at 10:00 using the registration form at CeBIL (copy to your browser):
AI in Medicine: Legal and Ethical Issues – University of Copenhagen (ku.dk)
Organized in collaboration with CeBIL- Centre for Advanced Studies in Biomedical Innovation Law and Nordic Permed Law (NPL).
Additional details
Virtual option via Zoom (link will be provided at registration)
Metro stop “Islands Brygge”
Parking at the University of Copenhagen parking lot
Meet the speakers
I. Glenn Cohen
I. Glenn Cohen, JD, PhD, is a Deputy Dean and James A. Attwood and Leslie Williams Professor of Law, Harvard Law School as well as the Faculty Director of the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics. His work focuses on how the law grapples with new medical technologies – including reproductive technologies, psychedelics, and artificial intelligence. He is co-PI of the Project on Precision Medicine, Artificial Intelligence, and the Law at the Petrie-Flom Center at Harvard Law School and a Core Partner at the University of Copenhagen’s Center for Advanced Studies in Biomedical Innovation Law (CeBIL).
Nicholson Price
Nicholson Price, JD, PhD, is a Professor of Law at the University of Michigan Law School. His work considers how various areas of law shape biomedical innovation, including the use of big data and artificial intelligence, drug manufacturing, and drug development. Heis co-PI of the Project on Precision Medicine, Artificial Intelligence, and the Law at the Petrie-Flom Center at Harvard Law School and a Core Partner at the University of Copenhagen’s Center for Advanced Studies in Biomedical Innovation Law (CeBIL).
Katharina Ó Cathaoir
Katharina Ó Cathaoir, PhD, is an Associate Professor of Law at the Faculty of Law, University of Copenhagen and Pro Futura Scientia Fellow at the Swedish Collegium for Advanced Study. Katharina’s work explores the rights of those at the margins of health law, including older people, children and migrants. She is particularly interested in the implications of data driven treatment for such groups, namely questions of access and acceptability.
Timo Minssen
Timo Minssen is Professor of Law at the University of Copenhagen and the Founder and Managing Director of the Center for Advanced Studies in Biomedical Innovation Law (CeBIL). As a leading European authority with close to 200 publications in the area, Timo is also an LML Research Affiliate with the University of Cambridge. His research and advisory practice concentrates on Intellectual Property-, Competition, Data Protection & Regulatory Law with a special focus on new technologies in the health & life sciences including artificial intelligence and quantum technology. His studies comprise a plethora of legal and ethical issues emerging in the lifecycle of relevant products and processes - from the regulation of responsible research and incentives for innovation to sustainable drug development, technology transfer and commercialization.
Program
Arrival, mingle & light refreshments
Introduction by CeBIL Director Timo Minssen: Medical AI and the work of (Inter-) CeBIL
Nicholson Price: Medical AI: Contextual bias, liability, and regulation
AI systems perform differently when used in different environments; how should the law respond? Are ex post liability rules adequate to create incentives for safe development and deployment, or can ex ante regulatory oversight resolve the problem from a different direction? As AI enters health use, policymakers, innovators, and health system actors alike should consider how to address the problems of contextual bias and differential performance.
Glenn Cohen: Label Bias, Informed Consent, Explainability, and Promise and Peril of ChatGPT
It is well-known that medical AI sometimes generates outcomes that are less good as to certain groups, especially racialized minority. But while data set bias is easy to conceptualize, how well-equipped are regulators and the law for more subtle forms of bias such as label bias? When are physicians legally or ethically obligated to inform patients that medical AI is involved in their care as a matter of informed consent? Should regulators be demanding explainability or interpretability in medical AI or is the black box defensible, and under what circumstances? Finally how might integration of Large Language Models (LLMs) such as ChatGPT raise particular challenges?
Katharina Ó Cathaoir: Medical AI: GDPR and informed consent in Nordic law
The explainability requirements of the GPDR have been widely discussed in academic literature. However, in European countries healthcare is mainly governed at the national level, which may set higher standards than what is mandated by EU law. Consequently, healthcare providers must adhere to domestic healthcare regulations when utilizing ML models to offer medical advice. What level of understanding must physicians have regarding such models in order to integrate them into patient care in a manner compliant with domestic law?
Q&A, Discussion & Mingle with light refreshments
Sign up for the event
If you have any other questions to the event please contact the organizer for the event at See registration link